SG11202007503WA - A process for enterovirus purification and inactivation and vaccine compositions obtained thereof - Google Patents

A process for enterovirus purification and inactivation and vaccine compositions obtained thereof

Info

Publication number
SG11202007503WA
SG11202007503WA SG11202007503WA SG11202007503WA SG11202007503WA SG 11202007503W A SG11202007503W A SG 11202007503WA SG 11202007503W A SG11202007503W A SG 11202007503WA SG 11202007503W A SG11202007503W A SG 11202007503WA SG 11202007503W A SG11202007503W A SG 11202007503WA
Authority
SG
Singapore
Prior art keywords
enterovirus
inactivation
purification
vaccine compositions
compositions obtained
Prior art date
Application number
SG11202007503WA
Other languages
English (en)
Inventor
Krishna Murthy Ella
Vijaya Kumar Daram
Original Assignee
Bharat Biotech Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Biotech Int Ltd filed Critical Bharat Biotech Int Ltd
Publication of SG11202007503WA publication Critical patent/SG11202007503WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32651—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32651—Methods of production or purification of viral material
    • C12N2770/32652—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32661—Methods of inactivation or attenuation
    • C12N2770/32663—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202007503WA 2018-02-07 2019-02-06 A process for enterovirus purification and inactivation and vaccine compositions obtained thereof SG11202007503WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841004703 2018-02-07
PCT/IN2019/050095 WO2019155492A1 (fr) 2018-02-07 2019-02-06 Procédé de purification et d'inactivation d'entérovirus et compositions de vaccin obtenues à partir de celui-ci

Publications (1)

Publication Number Publication Date
SG11202007503WA true SG11202007503WA (en) 2020-09-29

Family

ID=67548350

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007503WA SG11202007503WA (en) 2018-02-07 2019-02-06 A process for enterovirus purification and inactivation and vaccine compositions obtained thereof

Country Status (5)

Country Link
US (1) US11911457B2 (fr)
EP (1) EP3749757A4 (fr)
SG (1) SG11202007503WA (fr)
WO (1) WO2019155492A1 (fr)
ZA (1) ZA202005510B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3906051A4 (fr) * 2018-12-29 2022-09-28 Bharat Biotech International Limited Adaptation d'entérovirus à des cellules vero et formulations vaccinales associées
WO2022070210A1 (fr) * 2020-09-29 2022-04-07 Bharat Biotech International Limited Formulations stables de vaccins contre des entérovirus à faible abondance et leur procédé de fabrication
WO2022254459A1 (fr) * 2021-05-31 2022-12-08 Bharat Biotech International Limited Formulations de vaccin contre le coronavirus véhiculées par un virus rabique recombinant inactivé et additionné d'adjuvant(s)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525349A (en) 1981-12-29 1985-06-25 Societe Anonyme Dite: Institut Merueux Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
US6951752B2 (en) 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
EP1793852A1 (fr) * 2004-08-27 2007-06-13 Panacea Biotec Ltd. Vaccin antipoliomyélitique inactivé dérivé de la souche sabin du virus de la polio
AU2010272685B2 (en) * 2009-07-16 2015-02-26 Crucell Holland B.V. Production of polio virus at high titers for vaccine production
BR112013005049A2 (pt) * 2010-09-02 2016-05-31 Sanofi Pasteur estabilizador para a preparação de uma composição vacina da pólio seca injetável
CN105148285B (zh) * 2011-04-21 2019-02-12 塔夫茨大学信托人 用于活性试剂稳定化的方法和组合物
WO2012171026A2 (fr) 2011-06-10 2012-12-13 Biovest International, Inc. Procédés pour la production virale à haut rendement
CN105517568B (zh) * 2013-06-17 2020-07-07 由卫生福利和体育大臣代表的荷兰王国 防止病毒组分聚集的方法
EP3172317B1 (fr) * 2014-07-24 2019-05-01 Janssen Vaccines & Prevention B.V. Procédé de purification du virus de la poliomyélite à partir de cultures cellulaires
JP6755243B2 (ja) 2014-10-07 2020-09-16 セラム インスティチュート オブ インディア プライベイト リミテッド エンテロウイルス不活化およびアジュバント吸着のための改良された方法、ならびに、それから得られる投与量減量ワクチン組成物
MX2019002495A (es) * 2016-09-01 2020-02-17 Takeda Vaccines Inc Metodos para producir virus para la produccion de vacunas.

Also Published As

Publication number Publication date
US20200376110A1 (en) 2020-12-03
EP3749757A1 (fr) 2020-12-16
EP3749757A4 (fr) 2021-11-24
ZA202005510B (en) 2021-08-25
WO2019155492A1 (fr) 2019-08-15
US11911457B2 (en) 2024-02-27

Similar Documents

Publication Publication Date Title
HRP20190352T1 (hr) Novi 6-kondenzirani heteroarildihidropirimidini za liječenje i profilaksu infekcije virusom hepatitisa b
HK1251554A1 (zh) 用於治療和預防病毒感染的新的取代的氨基噻唑並嘧啶二酮
HK1248711A1 (zh) 用於治療和預防病毒感染的新的取代的氨基噻唑並嘧啶二酮
HK1223931A1 (zh) 用於治療和預防乙型肝炎病毒感染的新型二氫喹嗪酮類化合物
ZA202005510B (en) A process for enterovirus purification and inactivation and vaccine compositions obtained thereof
GB201814362D0 (en) Composition and process for preparing vaccine
IL282881A (en) Methods for treating hepatitis B infection
HRP20180639T1 (hr) Derivati izoindolina, namijenjeni upotrebi u liječenju virusne infekcije
HK1250480A1 (zh) 用於治療hbv感染的組合物和方法
ZA201903110B (en) Air pollutant treatment process
SG10202010814RA (en) Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
HK1252343A1 (zh) 用於治療病毒感染的組合物和方法
GB201806736D0 (en) Method for virus purification
ZA202101026B (en) Methods and compositions for producing a virus
EP3197465A4 (fr) Compositions et méthodes de traitement d'une infection virale
ZA201604784B (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection